Sanofi has worked hard to hold on to the big profits generated by its blockbuster insulin Lantus, but the onslaught of copies continues. Mylan and Biocon have now won an EU recommendation for approval of their biosimilar after overcoming manufacturing concerns that forced a delay last summer.Original Article
Mylan and Biocon win CHMP nod for Lantus biosimilar after getting beyond plant issues
